Aleor Dermaceuticals, a joint venture of Alembic Pharma gets the USFDA approval for its generic antifungal cream :
On 1 April 2021, Alembic Pharma made an announcement regarding its joint venture Aleor Dermaceuticals. It stated that the latter had received the USFDA’s approval for a generic antifungal cream. This generic version contains Nystatin and Triamcinolone Acetonide cream. It is used for the treatment of cutaneous candidiasis.
In a BSE filing, the pharma firm claimed that Aleor’s ANDA application for this product was approved by the USFDA. This product comprises Nystatin and Triamcinolone cream USP, 1,00,000 units/gram and 1 mg/gram. It is a generic version of Taro Pharmaceuticals Inc’s Nystatin and Triamcinolone Acetonide Cream USP of the same strength.
Per IQVIA, the estimated market size of this product is around USD 19 million for 12 months ending December 2020.
Alembic Pharma has over 139 ANDA approvals, of which 123 are final approvals and 16 are tentative approvals from the USFDA.
- 1. United States Food and Drug Administration
- 2. Bombay Stock Exchange
- 3. Abbreviated New Drug Application
- 4. United States Pharmacopoeia
- 5. Formerly known as Quintiles and IMS Health